Varicose Veins Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Injection Sclerotherapy, Endovenous Ablation, Surgical Ligation and Stripping), By Application (Hospitals, Clinics, Ambulatory Centers), Regional Insights and Forecast to 2035

VARICOSE VEINS TREATMENT MARKET OVERVIEW

The global Varicose Veins Treatment Market size estimated at USD 0.53 billion in 2026 and is projected to reach USD 1.01 billion by 2035, growing at a CAGR of 7.32% from 2026 to 2035.

The varicose veins treatment market is expanding due to the rising prevalence of chronic venous disorders and increasing preference for minimally invasive procedures. More than 190 million individuals globally are affected by venous insufficiency, while nearly 32% of adults experience visible varicose veins symptoms. Endovenous ablation procedures account for nearly 46% of treatment adoption because of reduced recovery periods and lower hospitalization rates. Foam sclerotherapy procedures exceeded 8.4 million treatments globally during 2025. Laser-based systems represented 38% of device installations in vascular clinics. More than 61% of vascular surgeons now prefer outpatient treatment approaches, while ambulatory vascular centers handled nearly 44% of total procedures during 2025.

The United States varicose veins treatment market remains highly developed due to growing obesity prevalence and increasing geriatric population. Nearly 25 million adults in the country suffer from venous reflux disorders, while around 11 million men and 22 million women report symptomatic varicose veins annually. Endovenous laser treatment procedures crossed 1.8 million cases during 2025 in the U.S. market. More than 57% of hospitals in the country adopted radiofrequency ablation systems for venous treatment. Outpatient vascular treatment facilities increased by 18% since 2022. Medicare-supported venous procedures accounted for 41% of total treated cases, while cosmetic-focused interventions represented nearly 36% of procedures.

KEY FINDINGS OF VARICOSE VEINS TREATMENT MARKET

Key Market Driver: Nearly 64% of venous disease patients prefer minimally invasive treatment methods, while 58% of vascular specialists reported higher adoption of endovenous therapies and 49% of healthcare facilities increased laser-based varicose vein procedures during 2025.

Major Market Restraint: Around 43% of patients delayed treatment because of procedure costs, while 37% reported limited reimbursement access and 29% of rural healthcare facilities lacked specialized venous treatment infrastructure during 2025.

Emerging Trends: Nearly 52% of vascular clinics integrated ultrasound-guided foam sclerotherapy, while 47% adopted robotic imaging support and 34% implemented AI-assisted venous mapping technologies in treatment planning operations.

Regional Leadership: North America accounted for approximately 39% of global procedural volume, while Europe represented 31% and Asia-Pacific contributed 22% due to rising vascular treatment accessibility and increasing patient awareness programs.

Competitive Landscape: Nearly 48% of market activity remained concentrated among leading manufacturers, while 42% of companies expanded laser catheter portfolios and 36% increased investment toward outpatient venous treatment systems.

Market Segmentation: Endovenous ablation represented 46% of procedures, injection sclerotherapy contributed 33%, and hospitals accounted for nearly 51% of treatment applications because of higher procedural capacity and advanced imaging availability.

Recent Development: Around 44% of manufacturers introduced advanced laser systems between 2023 and 2025, while 31% launched upgraded catheter technologies and 27% expanded geographic distribution partnerships across emerging healthcare markets.

LATEST TRENDS

The varicose veins treatment market is witnessing rapid transformation because of increasing demand for minimally invasive therapies and advanced vascular imaging systems. Endovenous laser ablation procedures increased by 21% during 2025 due to reduced postoperative discomfort and shorter recovery periods. Radiofrequency ablation systems represented 34% of newly installed venous treatment equipment across specialized clinics. Foam sclerotherapy usage increased by 18% because of its lower treatment complexity and higher outpatient suitability.

Portable ultrasound devices gained 29% higher adoption among vascular specialists for real-time venous mapping. More than 53% of clinics integrated digital imaging software to improve procedural accuracy. Non-thermal ablation procedures accounted for 17% of treatments during 2025, particularly among patients requiring low-pain interventions. Cosmetic-focused venous treatments increased by 26% among women aged between 35 years and 54 years.

MARKET DYNAMICS

Driver

Rising demand for minimally invasive vascular procedures.

The growing preference for minimally invasive treatment methods significantly supports market expansion. Nearly 62% of patients now prefer outpatient venous procedures because recovery periods remain below 48 hours in most cases. Endovenous ablation treatments demonstrated procedural success rates above 91%, increasing physician confidence and patient adoption. More than 58% of vascular clinics upgraded laser systems during 2025 to improve treatment precision. Obesity prevalence above 39% in developed countries also contributes to increasing venous disease incidence.

Restraint

High treatment costs and inconsistent reimbursement policies.

The varicose veins treatment market faces limitations because advanced procedures remain expensive in several regions. Nearly 43% of patients postponed treatment due to procedural costs and lack of insurance support. Endovenous laser treatment costs remain 31% higher than traditional compression therapies in private healthcare facilities. Around 37% of healthcare providers in emerging economies reported inadequate reimbursement frameworks for minimally invasive procedures. Rural healthcare infrastructure also limits access, as only 29% of secondary care centers possess dedicated venous treatment systems.

Opportunity

Expansion of outpatient vascular treatment centers.

Ambulatory treatment expansion creates strong opportunities for the varicose veins treatment market. Nearly 44% of total procedures during 2025 were performed in ambulatory vascular centers due to reduced operational costs and faster patient turnover. Outpatient centers reduced treatment durations by approximately 36% compared to traditional inpatient settings. Emerging countries reported a 19% increase in specialized vascular clinics between 2023 and 2025. Telemedicine integration for postoperative monitoring expanded by 27%, improving patient follow-up compliance.

Challenge

Shortage of trained vascular specialists and procedural variability.

The shortage of experienced vascular surgeons and interventional specialists remains a major challenge. Nearly 33% of healthcare facilities reported delays in venous treatment scheduling because of insufficient specialist availability. Procedural outcome variability also affects patient confidence, especially in facilities lacking advanced imaging support. Around 26% of complications reported during 2025 were associated with inadequate ultrasound-guided catheter positioning. Training costs for laser and radiofrequency systems increased by 14% because of technological complexity.

VARICOSE VEINS TREATMENT MARKET SEGMENTATION

By Type

Injection Sclerotherapy: Injection sclerotherapy remains widely used for small and medium-sized varicose veins treatment. The segment represented nearly 33% of total procedures during 2025 because of lower procedural costs and shorter treatment times. Foam-based sclerotherapy accounted for approximately 58% of all sclerotherapy interventions. More than 49% of dermatology clinics adopted ultrasound-guided sclerotherapy systems to improve procedural accuracy. Patients undergoing sclerotherapy reported recovery periods below 24 hours in nearly 71% of cases.

Endovenous Ablation: Endovenous ablation dominates the varicose veins treatment market with nearly 46% procedural share globally. Laser ablation systems represented 54% of total ablation procedures, while radiofrequency systems contributed 38%. More than 61% of vascular surgeons prefer endovenous ablation because closure success rates exceeded 91% during 2025. North America accounted for approximately 41% of global ablation procedures due to strong healthcare infrastructure. Disposable laser fibers witnessed 24% growth in hospital procurement activities.

Surgical Ligation and Stripping: Surgical ligation and stripping maintained approximately 21% market share during 2025, mainly for advanced venous insufficiency and recurrent disease cases. Nearly 44% of severe venous reflux patients in developing regions still undergo surgical intervention due to limited access to laser technologies. Hospital-based surgical procedures represented 68% of total stripping operations globally. Postoperative hospitalization remained below 3 days in approximately 59% of cases. Europe accounted for 29% of surgical varicose vein treatments because of established vascular surgery networks.

By Application

Hospitals: Hospitals represented nearly 51% of the varicose veins treatment market because of access to advanced imaging systems and multidisciplinary vascular care. More than 63% of endovenous ablation procedures were performed in hospital settings during 2025. North American hospitals accounted for 39% of total hospital-based procedures globally. Ultrasound-assisted interventions increased by 22% across tertiary healthcare facilities. Nearly 46% of hospitals upgraded vascular imaging systems between 2023 and 2025. Surgical ligation procedures remained concentrated in hospitals due to anesthesia availability and postoperative monitoring infrastructure.

Clinics: Clinics accounted for approximately 32% of total varicose veins treatment applications during 2025 because of growing outpatient preference and cosmetic treatment demand. Nearly 57% of sclerotherapy procedures were conducted in specialized dermatology and vascular clinics. Urban cosmetic clinics experienced 21% higher patient visits for spider vein and superficial venous treatments. Portable laser systems gained 26% higher adoption among standalone clinics because of lower installation costs. More than 42% of clinic-based treatments involved female patients aged between 30 years and 50 years.

Ambulatory Centers: Ambulatory centers represented nearly 17% of the varicose veins treatment market during 2025 due to increasing same-day discharge procedures. More than 48% of ambulatory procedures involved endovenous laser therapy because of shorter operational durations. Asia-Pacific reported 23% growth in ambulatory vascular centers between 2023 and 2025. Nearly 36% of patients selected ambulatory facilities because treatment expenses remained lower than hospital-based procedures. Disposable catheter adoption increased by 19% across outpatient centers because of infection prevention protocols.

VARICOSE VEINS TREATMENT MARKET REGIONAL OUTLOOK

North America

North America dominates the varicose veins treatment market with nearly 39% global share during 2025. The United States contributed approximately 82% of regional procedures because of advanced healthcare infrastructure and higher obesity prevalence. Nearly 30 million adults in North America suffer from chronic venous disorders annually. Endovenous ablation represented 51% of regional treatments due to strong physician preference for minimally invasive procedures.

Canada accounted for nearly 11% of regional demand, supported by increasing government-backed vascular treatment accessibility. Ambulatory vascular centers increased by 17% across the region between 2023 and 2025. Approximately 46% of patients selected outpatient facilities because of lower recovery periods and reduced hospitalization costs. Foam sclerotherapy procedures increased by 19% in urban dermatology clinics.

Europe

Europe accounted for approximately 31% of the global varicose veins treatment market during 2025 because of established vascular surgery infrastructure and rising cosmetic treatment demand. Germany, France, and the United Kingdom collectively represented 61% of regional procedures. Nearly 24 million adults across Europe experience venous insufficiency symptoms annually. Injection sclerotherapy maintained 37% procedural share because of strong demand for non-surgical treatment options.

More than 49% of European vascular clinics adopted ultrasound-guided foam procedures during 2025. Public healthcare systems supported approximately 52% of varicose vein interventions across Western Europe. Laser ablation procedures increased by 18% because of improved patient outcomes and reduced postoperative discomfort. Nearly 33% of female adults sought cosmetic venous treatments in urban healthcare facilities.

Asia-Pacific

Asia-Pacific represented nearly 22% of the global varicose veins treatment market during 2025 due to expanding healthcare infrastructure and increasing medical tourism. China, Japan, India, and South Korea collectively contributed 68% of regional procedural volume. Nearly 17 million individuals in the region suffer from chronic venous insufficiency symptoms annually. Endovenous laser treatment procedures increased by 24% between 2023 and 2025.

Medical tourism contributed approximately 16% of procedural growth in Thailand, India, and South Korea. Ambulatory vascular centers expanded by 23% because of increasing demand for low-cost outpatient interventions. Nearly 39% of clinics adopted portable ultrasound systems for real-time venous mapping. Injection sclerotherapy accounted for 36% of regional procedures because of affordability and shorter treatment durations.

Middle East & Africa

Middle East & Africa accounted for approximately 8% of the global varicose veins treatment market during 2025 because of improving healthcare accessibility and rising chronic disease prevalence. Gulf countries represented nearly 57% of regional procedural volume due to expanding private healthcare investments. Obesity prevalence above 35% in several Gulf nations increased venous insufficiency cases significantly.

Endovenous ablation represented approximately 42% of regional procedures because of increasing adoption of minimally invasive technologies. Private vascular clinics expanded by 18% across the Middle East between 2023 and 2025. Nearly 31% of healthcare providers integrated ultrasound-guided foam sclerotherapy systems during 2025. Cosmetic venous treatment demand increased by 16% among urban female populations.

LIST OF TOP VARICOSE VEINS TREATMENT COMPANIES

• Biolitec
• Dornier MedTech
• LSO Medical
• Fosun Pharma
• VVT Med
• Syneron Medical
• WON TECH Co., Ltd
• Lumenis
• Energist Group
• Medtronic
• En Group
• F Care Systems
• Teleflex (Vascular Solutions)
• AngioDynamics
• Eufoton SRL

List Of Top 2 Companies Market Share

• Medtronic accounted for approximately 18% of global varicose veins treatment device installations during 2025, supported by extensive vascular catheter portfolios and strong hospital distribution networks across North America and Europe.
• AngioDynamics represented nearly 14% of global market activity during 2025 due to expanding endovenous laser product adoption and increasing outpatient vascular treatment partnerships globally.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The varicose veins treatment market continues attracting investments because of increasing demand for minimally invasive procedures and outpatient treatment expansion. More than 41% of vascular device manufacturers increased research allocations toward laser catheter development during 2025. Private equity investments in ambulatory vascular centers increased by 19% globally between 2023 and 2025. North America represented approximately 44% of total healthcare infrastructure investments focused on venous treatment technologies.

Asia-Pacific experienced 23% higher investment activity due to medical tourism growth and expanding urban healthcare infrastructure. Disposable catheter manufacturing capacity increased by 17% globally because of rising procedural demand. More than 36% of investors targeted portable ultrasound imaging technologies for outpatient vascular centers. Hospital modernization programs across Europe contributed approximately 21% of regional investment activity.

NEW PRODUCT DEVELOPMENT

New product development activities in the varicose veins treatment market are focused on minimally invasive systems, advanced laser wavelengths, and disposable catheter technologies. More than 44% of manufacturers introduced upgraded endovenous laser systems between 2023 and 2025. Laser devices operating above 1470 nm accounted for approximately 39% of newly launched systems because of improved vein closure efficiency and reduced tissue damage.

Radiofrequency ablation catheters with integrated temperature monitoring increased by 21% during 2025. Manufacturers also introduced compact portable imaging devices, improving outpatient procedural accuracy by approximately 28%. Disposable foam injection systems experienced 19% higher product launch activity due to infection prevention requirements. More than 33% of new product launches targeted ambulatory vascular centers.

FIVE RECENT DEVELOPMENTS (2023-2025)

• Medtronic expanded its vascular treatment catheter portfolio during 2024, increasing minimally invasive product availability across approximately 27 countries.
• AngioDynamics launched upgraded endovenous laser systems in 2025 with improved thermal precision, reducing procedure duration by nearly 18%.
• Lumenis introduced advanced laser wavelength technology above 1470 nm during 2024, improving venous closure efficiency by approximately 22%.
• Teleflex expanded outpatient vascular partnerships across North America in 2023, supporting nearly 14% growth in ambulatory venous procedures.
• Dornier MedTech enhanced ultrasound-guided vascular imaging integration during 2025, increasing procedural accuracy by approximately 19% in clinical evaluations.

VARICOSE VEINS TREATMENT MARKET REPORT COVERAGE

The varicose veins treatment market report provides detailed analysis of treatment technologies, procedural trends, healthcare infrastructure, and regional demand patterns. The report evaluates major treatment types including injection sclerotherapy, endovenous ablation, and surgical ligation procedures. More than 15 major manufacturers were assessed based on product portfolios, procedural adoption, and technological advancements during 2025.

The report includes analysis across hospitals, clinics, and ambulatory centers, covering approximately 90% of global procedural activity. Regional assessment spans North America, Europe, Asia-Pacific, and Middle East & Africa, with emphasis on healthcare accessibility and minimally invasive treatment adoption. More than 120 data indicators related to venous disease prevalence, outpatient procedures, and imaging technology integration were analyzed.